Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Novartis
|
| gptkbp:acquisitionYear |
2020
|
| gptkbp:focus |
gptkb:cardiovascular_disease
gptkb:disease |
| gptkbp:founded |
1996
|
| gptkbp:founder |
gptkb:Clive_Meanwell
|
| gptkbp:headquarters_location |
gptkb:Parsippany,_New_Jersey,_United_States
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:notableProduct |
gptkb:Angiomax
gptkb:Inclisiran |
| gptkbp:numberOfEmployees |
over 400 (as of 2019)
|
| gptkbp:stockSymbol |
gptkb:MDCO
|
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:website |
www.themedicinescompany.com
|
| gptkbp:bfsParent |
gptkb:Rempex_Pharmaceuticals
|
| gptkbp:bfsLayer |
5
|
| https://www.w3.org/2000/01/rdf-schema#label |
The Medicines Company
|